Want tender expert help? See our tender preparation service
Tenders

Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes

Closed
Deadline
Deadline not specified
Contract Details
Category
Open Procedure
Reference
045358-2026
Value
£1,387,430
Location
United Kingdom
Published
August 24, 2026
Organization
CPV Code
Project Timeline

Tender Published

May 18, 2026

Buyer IntelligencePRO
🔒
Unlock Buyer Intelligence
See spending patterns, preferred procedures, and more.
Upgrade to Professional →
Budget
£1,387,430
Duration
Not specified
Location
United Kingdom
Type
Open Procedure

Original Tender Description

This is a notice of intention to make an award. NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU),on behalf of NHS England Specialised Commissioning (referred to as the Authority) invited suitably qualified and experienced providers to express interest in the provision of Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes by responding to this accreditation process.<br/><br/>Services are being commissioned across seven (7) geographical regions to serve the population of England, as outlined below:<br/><br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>- There is no restriction on the number of sites that may be commissioned.<br/>- Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.<br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>Inherited cancer predisposition syndromes are genetic conditions that increase the risk of developing one or more types of cancer. Scanning will be commissioned for three rare inherited cancer predisposition syndromes; Li-Fraumeni syndrome (LFS), constitutional mismatch repair deficiency syndrome (CMMRD) and rhabdoid tumour predisposition syndrome (RTPS).<br/><br/>Published clinical guidelines for these conditions recommend the use of regular whole-body MRI (WBMRI) with the aim of detecting cancers at an early stage. The provision of expanded capacity for WBMRI scanning aims to improve clinical care of individuals once an inherited cancer predisposition has been diagnosed.<br/><br/>Providers will:<br/>• Provide, interpret and report WB-MRI Scanning for the patient cohort described.<br/>• Provide, interpret, and report brain MRI Scanning (the first one with contrast when possible).<br/>• Establish effective pathways (including sharing results) with providers.<br/>• Be linked to regional genetic centres to allow continuity of care.<br/>• Facilitate communication with referrers including consultant clinical geneticists<br/>• Have capacity to plan and undertake WBMRI under general anaesthetic if re-quired.<br/>• Have information governance processes that permit sharing clinical and imaging data across organisations involved with providing a cancer surveillance service, and collection of clinical outcome and monitoring data.<br/>• Engage positively with associated patient support groups.<br/>• Ensure clear communication with Genetics Services and patients, to support patients to make decisions on where to access screening.<br/>• Work collaboratively with other organisations e.g. within imaging networks, to provide scanning and reporting capacity and expertise to meet the needs of their population including transition between paediatric and adult services.<br/>• Operate Quality Assessment processes according to CQC standards<br/>• Screening will be in addition to breast screening undertaken through the National VHRS Programme<br/>• Provide facilities will be in line with NHS guidance on Facilities for diagnostic imaging and interventional radiology.<br/>• Support continued educational initiatives for non-genetics healthcare professionals to improve expertise and understanding of cancer predisposition syndromes.<br/>• Liaise with partners across cancer alliances to support early diagnosis innovation opportunities<br/>• Ensure screening frequency will be in accordance with surveillance protocols.

Risk Analysis

Risk analysis is not yet available for this country's tenders. Currently supported: Estonia, Latvia, Lithuania, Poland, France, UK, Denmark, Netherlands, Norway, and Finland.

Win Strategy

Get an AI-powered winning strategy tailored to this tender. Includes win probability score, key opportunities and challenges, recommended bid focus areas, competitive positioning insights, and actionable recommendations to maximize your chances.

Login

Competitors

Upgrade to see which companies are likely to bid on this tender, based on historical procurement data.

Login

Requirements & Qualifications

AI extracts and organizes all requirements from tender documents — mandatory qualifications, technical specifications, financial conditions, and submission rules — clearly categorized so you know exactly what's needed to bid.

Login

Basic Requirements

  • Company registration in EU required
  • Proven track record in similar projects
  • Financial stability documentation

Documents

3 documents available with AI summaries

OCDS RecordDOC
045358-2026_ocds_record.json

No summary available for this document.

OCDS Release PackageDOC
045358-2026_ocds_release.json

No summary available for this document.

Official PDF VersionPDF
045358-2026_official.pdf

No summary available for this document.

Documents Preview

Sign up to view document summaries and analysis

Quality Score

Comprehensive quality analysis of this tender scoring legal compliance, clarity, completeness, fairness, practicality, data consistency, and sustainability on a 0-100 scale with detailed breakdown and recommendations.

Login

Add to Pipeline